Characteristics | Stable COPD n = 53 | AE-COPD n = 44 | p value |
---|---|---|---|
Age, years (range) | 67.9 (48-81) | 69.5 (46-86) | 0.402 |
Gender, males % | 60.3 | 56.8 | 0.723 |
Current smokers, n (%) | 15 (28.3) | 13 (29.5) | 0.471 |
Smoking history (Pack-years), mean (SD) | 53.10 (23.83) | 48.87 (34.1) | 0.080 |
Severity of COPD – GOLD Stage |  |  | 0.109 |
I (FEV1 ≥ 80 % predicted), n | 6 | 2 |  |
II (50 % predicted ≤ FEV1 ≤ 80 % predicted), n | 20 | 14 |  |
III (30 % predicted ≤ FEV1 ≤ 50 % predicted), n | 14 | 21 |  |
IV (FEV1 ≤ 30 % predicted), n | 13 | 6 |  |
VC % predicted (SD) | 89.6 (21.4) | 87.7 (17.8) | 0.658 |
FEV1 % predicted (SD) | 50.3 (21.5) | 48.0 (15.9) | 0.543 |
FEV1/VCmax (SD) | 43.3 (13.7) | 43.8 (13.7) | 0.846 |
TLC % predicted (SD) | 114.7 (22.3) | 111.9 (20.0) | 0.721 |
RV % predicted (SD) | 162.8 (61.5) | 157.6 (45.1) | 0.290 |
DLCO % predicted (SD) | 48.3 (19.2) | 45.7 (18.3) | 0.507 |
RV/TLC (SD) | 0.55 (0.11) | 0.56 (0.09) | 0.988 |
paO2, kPa (SD) | 8.8 (1.5) | 9.2 (1.5) | 0.294 |
paCO2, kPa (SD) | 5.3 (0.8) | 5.2 (0.8) | 0.399 |
HbCO % (SD) | 2.6 (2.5) | 2.2 (2.1) | 0.414 |
CT scan assessment, n | 29 | 32 | Â |
Bronchiectasis | 4 | 7 | |
Moderate emphysema | 9 | 10 | |
Severe emphysema | 17 | 17 | |
COPD-medication, n (%) | Â | Â | |
SABA | 11 (21) | 10 (23) | 0.768 |
LABA | 7 (13) | 5 (11) | 0.816 |
LAMA | 8 (15) | 14 (32) | 0.043 |
SABA + LAMA | 10 (19) | 12 (28) | 0.295 |
LABA + ICS | 37 (70) | 28 (65) | 0.625 |
ICS | 3 (6) | 5 (12) | 0.460 |
oral corticosteroids | 18 (34) | 19 (44) | 0.306 |
Xanthines | 2 (4) | 1 (2) | 1.000 |
Mucolytics | 5 (9) | 11 (26) | 0.035 |
LTOT | 11 (21) | 12 (28) | 0.414 |